Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.

Rabea Asleh,Alfredo L Clavell,Naveen L Pereira,Byron Smith,Alexandros Briasoulis,Hilmi Alnsasra,Walter K Kremers,Thomas M Habermann,Clark C Otley,Xin Li,Brooks S Edwards,John M Stulak,Richard C Daly,Sudhir S Kushwaha

Journal of the American College of Cardiology（2019）

引用 34|浏览38

暂无评分

摘要

Conversion to SRL was associated with a decreased risk of all de novo malignancies, PTLD, and subsequent primary occurrences of NMSC after HT. These findings provided further explanation of the late survival benefit with long-term SRL use.

查看译文

关键词

heart transplantation,immunosuppression,malignancy,sirolimus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要